Bivalirudin in acute coronary syndromes and percutaneous coronary intervention: should we use it?

Area of Science:

• Cardiology
• Interventional Cardiology
• Pharmacology

Background:

• Major bleeding is a critical risk factor in percutaneous coronary intervention (PCI) for acute coronary syndromes (ACS), leading to increased morbidity, mortality, and healthcare costs.
• Preventing bleeding is now a primary goal, comparable to preventing ischaemia, due to its significant impact on patient outcomes.
• Bivalirudin, a direct thrombin inhibitor, has demonstrated efficacy in reducing ischaemic events and notably, is associated with a lower incidence of bleeding.

Purpose of the Study:

• To review the existing evidence supporting the use of bivalirudin in various coronary syndromes and PCI procedures.
• To provide guidance on the application of bivalirudin, particularly in high-risk patient subgroups and complex coronary syndromes.

Main Methods:

• Systematic review of clinical trials and observational studies evaluating bivalirudin in ACS and PCI.
• Analysis of data comparing bivalirudin with other anticoagulants regarding efficacy (ischaemia reduction) and safety (bleeding events).

Main Results:

• Bivalirudin effectively reduces ischaemic events in patients undergoing PCI for ACS.
• A significant reduction in major bleeding complications is observed with bivalirudin compared to other anticoagulation strategies.
• Evidence supports bivalirudin's utility across the spectrum of ACS and PCI, including high-risk populations.

Conclusions:

• Bivalirudin is a valuable therapeutic option for ACS patients undergoing PCI, offering a favorable balance between ischaemia control and bleeding reduction.
• The review supports the expanded use of bivalirudin, with a proposed algorithm to guide its application in specific clinical scenarios.
• Optimizing anticoagulation with bivalirudin can improve patient outcomes by mitigating the risks associated with major bleeding during PCI.